Literature DB >> 17269854

Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses.

Deborah T Gold1.   

Abstract

OBJECTIVE: To define medication adherence and describe the limitations of various assessment methods, reasons for nonadherence to medications used to manage chronic illness, the impact of nonadherence to osteoporosis medications, and strategies for improving medication adherence.
BACKGROUND: Medication nonadherence is a major public health problem that adversely affects patient outcomes and increases health care utilization and costs. Postmenopausal osteoporosis is a chronic disease, and adherence to drug therapy used to manage the disease is as much of a challenge as it is in other chronic diseases.
SUMMARY: Medication adherence reflects both compliance and persistence. Direct assessment methods (e.g., observation, laboratory serum drug assays) are more accurate than indirect methods, but they are more costly and often impractical. Indirect methods include patient self-report and the use of prescription refill records, pill counts, and electronic monitoring devices. Medication adherence in patients with postmenopausal osteoporosis or other chronic illnesses is less than optimal. Adverse effects, financial constraints, mis-communication with the prescriber, and a perception that medications are unnecessary are among the possible reasons for medication nonadherence. Unintentional nonadherence is a passive process, often simply forgetting, and intentional nonadherence is an active process involving a deliberate choice, often based on adverse effects or a perceived lack of benefit.
CONCLUSIONS: Nonadherence to osteoporosis medications can adversely affect patient outcomes and increase health care utilization and costs. An individualized approach to improving medication adherence based on patient preferences and readiness to change is needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17269854     DOI: 10.18553/jmcp.2006.12.S6-A.S20

Source DB:  PubMed          Journal:  J Manag Care Pharm        ISSN: 1083-4087


  11 in total

1.  Acromegalic patients lost to follow-up: a pilot study.

Authors:  Leandro Kasuki; Nelma Verônica Marques; Maria José Braga La Nuez; Vera Lucia Gomes Leal; Renata N Chinen; Mônica R Gadelha
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

2.  New dosing options in osteoporosis treatment: clinical evidence on Risedronate 75mg monthly treatment.

Authors:  Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

Review 3.  A new taxonomy for describing and defining adherence to medications.

Authors:  Bernard Vrijens; Sabina De Geest; Dyfrig A Hughes; Kardas Przemyslaw; Jenny Demonceau; Todd Ruppar; Fabienne Dobbels; Emily Fargher; Valerie Morrison; Pawel Lewek; Michal Matyjaszczyk; Comfort Mshelia; Wendy Clyne; Jeffrey K Aronson; J Urquhart
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

4.  Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment.

Authors:  L Boudou; B Gerbay; F Chopin; E Ollagnier; P Collet; T Thomas
Journal:  Osteoporos Int       Date:  2011-04-29       Impact factor: 4.507

5.  Antioxidative effect of aspirin on vascular function of aged ovariectomized rats.

Authors:  Buket Demirci; Omer Demir; Turhan Dost; Mustafa Birincioglu
Journal:  Age (Dordr)       Date:  2013-07-20

6.  Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications.

Authors:  E Barrett-Connor; K Ensrud; A N A Tosteson; S F Varon; M Anthony; N Daizadeh; S Wade
Journal:  Osteoporos Int       Date:  2008-07-08       Impact factor: 4.507

7.  Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures.

Authors:  S Morin; E Rahme; H Behlouli; A Tenenhouse; D Goltzman; L Pilote
Journal:  Osteoporos Int       Date:  2007-07-19       Impact factor: 4.507

8.  Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.

Authors:  Leslie Hazel-Fernandez; Anthony M Louder; Shonda A Foster; Claudia L Uribe; Russel T Burge
Journal:  BMC Musculoskelet Disord       Date:  2013-01-03       Impact factor: 2.362

9.  The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy.

Authors:  Ewa Sewerynek; Hanna Horst-Sikorska; Wioletta Stępień-Kłos; Agnieszka Antkowiak; Małgorzata Janik; Karol Cieślak; Michalina Marcinkowska; Agnieszka Cegłowska; Michał Stuss
Journal:  Arch Med Sci       Date:  2013-04-22       Impact factor: 3.318

10.  The Minimal Clinically Important Difference in Glaucoma Medication Adherence: Interviews of Glaucoma Experts.

Authors:  Ajay Kolli; Shelby Daniel-Wayman; Paula Anne Newman-Casey
Journal:  Ophthalmic Res       Date:  2020-11-10       Impact factor: 3.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.